Articles from PESG Research

PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQSLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion’s latest announcement, detailing its collaboration with Evonik to develop an advanced siRNA PLGA microparticle formulation for SIL-204, marks another strategic milestone in its quest to transform cancer treatment. This comes as the precision oncology industry experiences rising M&A activity and robust demand for groundbreaking therapies.

PESG research releases a market alert covering Steakholder Foods (Nasdaq: STKH): Steakholder Foods a leader in alternative proteins and 3D printing technologies, has approved up to $1 million in crypto-currency purchases, as part of its treasury strategy. CEO Arik Kaufman describes the move as forward-thinking, aligning with the growing institutional adoption of digital assets and the recent approval of cryptocurrency ETFs. This strategic step not only underscores Steakholder’s innovative ethos but could also enhance its financial flexibility.

Steakholder Foods (NASDAQSTKH), a pioneer in alternative proteins and 3D food printing technologies, has recently transitioned from research and development to commercialization, marking a significant milestone in its journey toward profitability. This shift is underscored by strategic partnerships, product innovations, and the establishment of revenue streams, positioning the company at the forefront of the rapidly expanding alternative protein market.

Nuvectis Pharma (NASDAQNVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial targeting platinum resistant, ARID1a-mutated ovarian cancer, with a data update expected soon. This pipeline of innovative candidates has positioned Nuvectis at the forefront of precision oncology, and the market appears to be starting to take more notice as the company approaches important clinical milestones. Please refer to the disclaimers and disclosures also linked at the end of the report which it is subject to. Nothing contained herein is intended to serve as financial or investment advice.

Summit Therapeutics’ Breakthrough with Ivonescimab

Silexion Therapeutics (NASDAQSLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp NASDAQ: MACANASDAQMACA)

The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within this space. This report explores the anticipated effects of the reform on medical cannabis companies, with a spotlight on InterCure as an illustrative example of a company poised to benefit. It also briefly touches upon the broader industry anticipation of potential policy announcements from the U.S. before November.

PESG Research, a research group under the Future Markets Research Tank (FMRT), in proud to release an industry report on the emerging cultured food market, featuring Steakholder Foods (NASDAQSTKH), an innovative cultured meat leader. To read the full report, click here: https://bit.ly/3XiW5PO